Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5% – Should You Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares traded up 8.5% on Wednesday . The company traded as high as $4.53 and last traded at $4.4810. 1,028,076 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 2,727,517 shares. The stock had previously closed at $4.13.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TSHA. Needham & Company LLC lifted their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Raymond James Financial reissued a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, Wall Street Zen upgraded shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.09.

Taysha Gene Therapies Stock Performance

The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The stock has a fifty day moving average price of $4.61 and a two-hundred day moving average price of $4.58. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -13.37 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Taysha Gene Therapies had a negative return on equity of 56.64% and a negative net margin of 1,144.97%.The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. As a group, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the sale, the chief financial officer directly owned 1,443,786 shares in the company, valued at $6,655,853.46. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $190,448.32. Following the transaction, the chief executive officer directly owned 2,908,257 shares in the company, valued at $13,407,064.77. The trade was a 1.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 598,623 shares of company stock worth $2,822,188 over the last ninety days. 3.78% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. B Group Inc. increased its stake in Taysha Gene Therapies by 43.4% in the second quarter. B Group Inc. now owns 1,800,556 shares of the company’s stock valued at $4,159,000 after purchasing an additional 545,000 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $1,890,000. GSA Capital Partners LLP increased its stake in shares of Taysha Gene Therapies by 969.0% during the 3rd quarter. GSA Capital Partners LLP now owns 477,749 shares of the company’s stock valued at $1,562,000 after acquiring an additional 433,059 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $6,207,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $462,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.